Metastatic Digestive System Neuroendocrine Tumor G2
generalDigestive system neuroendocrine tumor G2 that has spread from its original site of growth to another anatomic site.
10
Centers
10
Active Trials
—
Cancer Funding
Specific Cancer Types(1)
| Name | Centers |
|---|---|
| Metastatic Pancreatic Neuroendocrine Tumor G2 | — |
Top Centers for Metastatic Digestive System Neuroendocrine Tumor G2(10)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 55.0 |
| 2 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 55.0 |
| 3 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 55.0 |
| 4 | NCI Clinical Active Research Program | 55.0 |
| 5 | University of Illinois Cancer CenterChicago, IL Active Research Program | 55.0 |
| 6 | University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive Active Research Program | 55.0 |
| 7 | Cancer Center at IllinoisUrbana, IL Active Research Program | 55.0 |
| 8 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program | 55.0 |
| 9 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 55.0 |
| 10 | BC CancerVancouver, BC Active Research Program | 55.0 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →